Ensifentrine (Ohtuvayre), a novel medication for the treatment of chronic obstructive pulmonary disease (COPD) recently approved by the US Food and Drug Administration, has been shown to reduce COPD ...
Add Yahoo as a preferred source to see more of our stories on Google. A new COPD drug, developed by Verona Pharma, was approved by the FDA Wednesday. The drug, ensifentrine, is the first new type of ...
(StatePoint) More than 11 million people in the United States are living with chronic obstructive pulmonary disease (COPD), including more than 3 million people with emphysema, a type of COPD. This ...
AJMC®: What recent developments in the therapeutic landscape of chronic obstructive pulmonary disease (COPD) do you think have the greatest potential to shift how treatment is managed? Dr Martinez: ...
FLORENCE, Italy — Exacerbations remain one of the major unresolved challenges in the management of chronic obstructive pulmonary disease (COPD), despite the introduction of new therapies. However, ...
While COPD (chronic obstructive pulmonary disease) symptoms may start out as mild to moderate — with episodes of difficulty breathing that come and go — over time, COPD tends to get worse, and many ...
A new COPD drug, developed by Verona Pharma, was approved by the FDA Wednesday. The drug, ensifentrine, is the first new type of maintenance treatment for COPD in over a decade. In clinical trials, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results